NEW YORK (Reuters Health) – In a first-in-human trial, a nanotherapeutic, NU-0129, penetrated the blood-brain barrier after infusion into eight patients with recurrent glioblastoma, showing some efficacy and no severe side effects. “This is the first time a nanotherapeutic has been shown to cross the blood-brain barrier when given through intravenous infusion,” Dr. Priya Kumthekar